Breast Cancer Research and Treatment

, Volume 30, Issue 1, pp 95–102 | Cite as

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

  • Laurence M. Demers


Fadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active aromatase inhibitors currently being evaluated as second line treatment of patients with hormone dependent forms of metastatic breast cancer. In a phase I clinical efficacy study, we examined the ability of these two imidazole derivatives to suppress the synthesis of estrogen in a cohort of postmenopausal patients with metastatic breast cancer. Both medications at relatively low doses were potent and rapid inhibitors of aromatase activity as evidenced by their ability to suppress the level of blood and urine estradiol and estrone as well as blood estrone sulfate in these patients. Letrozole appeared to be the more potent of the two, with over 95% suppression of both plasma and urinary estrogens observed within 2 weeks of therapy. Letrozole appeared to be more selective than Fadrozole in inhibiting aromatase activity in that no compromise in cortisol and aldosterone output was evident with Letrozole therapy at all of the doses tested, a compromise clearly seen with Fadrozole.

The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.

Key words

breast cancer aromatase inhibitors CGS 20267 CGS 16949A hormone ablative therapy breast cancer treatment endocrine therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 11:221–265, 1990.Google Scholar
  2. 2.
    Longcope C, Pratt JH, Schneider SH, Fineberg SE: Aromatization of androgens by muscle and adipose tissuein vivo. J Clin Endocr Metab 46:146–150, 1978.Google Scholar
  3. 3.
    Santen RJ, Worgul TJ, Samojlik E, et al: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–551, 1981.Google Scholar
  4. 4.
    Santen RJ: Clinical use of aromatase inhibitors in breast carcinoma.In: Holland JF, Frei III E, Best RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine, 3rd Ed. Lea and Febiger, Philadelphia, 1993, pp 865–877.Google Scholar
  5. 5.
    Goss PE, Powles TJ, Dowsett M, Hutchinson G, Brodie AMH, Gazet JC, Coombes RC: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxy androstenedione: Phase II report. Cancer Res 46:4823–4826, 1986.Google Scholar
  6. 6.
    Santen RJ, Demers LM, Adlercreutz H, Santner S, Sanders S, Lipton A: Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocr Metab 68:99–106, 1989.Google Scholar
  7. 7.
    Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C, Santen RJ: The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Molec Biol 44:687–691, 1993.Google Scholar
  8. 8.
    Lipton A, Santen JR: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33:503–511, 1974.Google Scholar
  9. 9.
    Stein RC, Dowsett M, Davenport J, Hadley A, Ford HT, Gazet JC, Coombes RC: Preliminary study of the treatment of advanced breast cancer in post-menopausal women with the aromatase inhibitor CGS 16949A. Cancer Res 50:1381–1384, 1990.Google Scholar
  10. 10.
    Raats JI, Falkson G, Falkson HC: A study of fadrozole. A new aromatase inhibitor on postmenopausal women with advanced breast cancer. J Clin Oncol 10:111–116, 1992.Google Scholar
  11. 11.
    Dowsett M, Stein RC, Mehta A, Coombes RC: Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in post menopausal breast cancer patients. Clin Endocrinol 32:623–634, 1990.Google Scholar
  12. 12.
    Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha M, Kochak GM, Fitzsimmons S, Sanders SI, Santen RJ: A phase I trial of CGS 16949A: A new aromatase inhibitor. Cancer 65:1279–1285, 1990.Google Scholar
  13. 13.
    Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Miller AA: Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocr Metab 73:99–106, 1991.Google Scholar
  14. 14.
    Demers LM, Welby JC, Wilson TE, Lipton A, Harvey HA, Santen RJ: The effects of CGS 16949A, an aromatase inhibitor, on adrenal mineralocorticoid biosynthesis. J Clin Endocr Metab 70:1162–1166, 1990.Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Laurence M. Demers
    • 1
  1. 1.Department of Pathology and Medicine, The M.S. Hershey Medical CenterThe Pennsylvania State UniversityHersheyUSA

Personalised recommendations